Clinical Trial

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Name: Cabozantinib for Patients With Recurrent or Progressive Meningioma — clinical trial record (NCT05425004)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

Protocol Amendment History 1 change

notable Primary completion pushed: 2026-10 -> 2026-12 2026-05-15

Trial Details

NCT Number	NCT05425004
Lead Sponsor	Baptist Health South Florida Collaborators: Exelixis
Conditions	Meningioma
Enrollment	24 participants
Start Date	2022-06-01
Primary Completion	2026-12 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-14